ClinicalTrials.gg
Not yet recruitingNCT06656260Updated Oct 24, 2024

Validation of Ocular Pain Questionnaire: Single-center, Prospective Observational Study

An observational study in Ocular Pain, OSDI and OPAS, sponsored by IRCCS Ospedale San Raffaele. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by IRCCS Ospedale San Raffaele · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
333
Sex
All
01

Study summary

This study will be a single-center, observational, prospective validation study with survey and sample characteristics comparable to similar validation studies in the literature.

Pain represents a physiological response to the presence of tissue damage and is associated with numerous pathological conditions of the ocular surface.

Furthermore, in the presence of dysfunction of the nociceptive system, ocular pain can occur chronically with neuropathic features.

Pain quantification systems used to guide symptomatic therapy include the Ocular Surface Disease Index (OSDI); the Ocular Pain Assessment Survey (OPAS); and the Standardized Patient Evaluation of Eye Dryness (SPEED).

The OSDI assesses the presence of ocular symptoms, their impact on activities of daily living, and the presence of any aggravating factors. Although it is used in clinical practice and research activities in a translated version, it has never been validated in Italian.

The OPAS studies in more detail the characteristics of pain and associated symptoms and their impact on the patient's overall quality of life. This instrument has neither been translated nor validated in an Italian version.

The failure to validate the OSDI and OPAS questionnaires in the Italian version marks the starting point for this validative study.

The SPEED questionnaire, already translated and validated in Italian, will be used as the Gold Standard and will allow comparison of the other instruments.

Finally, six questions regarding imaginary scenarios of pain experiences will be proposed to assess the individual threshold of nociceptive sensitivity taken from the Pain Sensitivity Questionnaire (two for mild pain assessment, two for intermediate intensity stimuli, and two for intense pain situations).

Therefore, the primary objective of the study is to validate the Italian version of the OSDI and OPAS questionnaires while the secondary objective is to analyze the responses to the questionnaires by subgroups of general sensitivity to nociceptive stimuli.

02

Conditions studied

  • Ocular Pain
  • OSDI
  • OPAS

Browse trials for

Keywords

  • Ocular pain
  • OSDI
  • OPAS
  • Questionnaire
03

In context

Eye Pain

31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.

Browse Eye Pain studies →

Lead sponsor

IRCCS Ospedale San Raffaele is the lead sponsor of 37 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A cohort of patients with corneal and ocular surface diseases referred to the Ophthalmology O.U. - Cornea Center of IRCCS Ospedale San Raffaele will be studied.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NA

Exclusion criteria

Exclusion Criteria:

  • NA
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
333 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to validate the Italian version of the OSDI and OPAS questionnaires.

    Time frame: The questionnaire will be acquired at day 0 (first time-point) and at day 7 (second time-point)

Secondary outcomes

  1. Secondary objective is the analysis of questionnaire responses by subgroups of general sensitivity to nociceptive stimuli.

    Time frame: The questionnaire will be acquired at day 0 (first time-point) and at day 7 (second time-point)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Nov 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Oct 24, 2024
StartEst.
Nov 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06656260
Lead sponsor
IRCCS Ospedale San Raffaele
Responsible party
Giulio Ferrari (Professor of Ophthalmology-San Raffaele Vita Salute University, Cornea and Ocular Surface Unit; Head-Eye Repair Lab San Raffaele Scientific Institute, IRCCS Ospedale San Raffaele) — Principal investigator
First posted
Oct 24, 2024
Start date
Nov 2024 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Oct 24, 2024

Study contacts

Giulio Ferrari, Medical Doctor
Contact
ferrari.giulio@hsr.it
+39 0226436186

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion